In short
Clinical trials are studying 2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOCYTIDYLYL-(3'-O->5'-O)-SPL84-23-1 as an inhaled study drug for people with cystic fibrosis. The trial is looking at safety, tolerability, and early signs of benefit. It also includes adults with cystic fibrosis and uses a placebo for comparison.
Key points
- Clinical trials are studying 2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOCYTIDYLYL-(3'-O->5'-O)-SPL84-23-1 as an inhaled treatment for cystic fibrosis. The study is Phase 2 and includes 22 participants. It is suspended, and the main focus is safety, tolerability, early benefit, and immune response.
Clinical trial overview
This trial studies 2'-O-(2-METHOXYETHYL)-5-METHYL-P-THIOCYTIDYLYL-(3'-O->5'-O)-SPL84-23-1, also named SPL84 in the trial title, for people with cystic fibrosis. The study uses an inhaled form and compares it with a placebo solution for inhalation.
The trial is designed to look at safety, tolerability, and preliminary efficacy, which means early signs that the treatment may help.
Study design and phase
This is an interventional study, which means researchers assign the study treatment to participants instead of only observing what happens.
It is a Phase 2 trial with 22 planned participants.
The brief summary says the study is testing multiple ascending doses by inhalation and aims to identify the maximum tolerated dose, or the highest dose that can be given without unacceptable problems in the study.
Who can participate
The target population is patients with cystic fibrosis.
The source data does not give more details about age, sex, or other entry rules, so only the condition-based population is known from the trial record.
What the study measures
The primary outcome includes the incidence, nature, and severity of adverse events, adverse events of special interest, and serious adverse events.
The study also measures changes from baseline, which means change from the starting point, in vital signs, clinical laboratory values, electrocardiogram (ECG), physical examination, sputum microbiology, and pulmonary function.
Another endpoint is immunogenicity, which means whether the body makes an immune response to the study treatment.
These measures help researchers understand both how the treatment is tolerated and whether there are early signs of benefit in the lungs and overall health.
Study status
The trial status is suspended.
This means the study is not currently active based on the source record.
